KingstronBio is a platform company specializing in innovative medical devices for structural heart disease. Our product portfolio includes surgical bioprosthetic valves, valve annuloplasty rings, biological patches, transcatheter aortic valve system, interventional mitral valves, and interventional tricuspid valves, making it one of China's most comprehensive companies in the industry. As one of the few domestic innovators started with the surgical valve product line, the company has accumulated extensive valve processing and manufacturing expertise through early-stage R&D, developing a unique and profound understanding of valve characteristics. To date, our surgical product line—including valve annuloplasty rings, surgical bioprosthetic valves, and cardiac surgical biological patches—has been launched into the market. In terms of transcatheter products, we have already obtained the first Chinese license of the third-generation transcatheter aortic valve.

KingstronBio has recently closed over 300 million yuan in Series C financing, led by Sequoia Capital China with participation from Everbright Financial Holdings and GF Capital. This funding will accelerate the R&D and commercialization of innovative transcatheter mitral and tricuspid valve products, as well as the scaled production of existing surgical products and third-generation transcatheter aortic valves.